An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene

Bexarotene is an FDA-approved drug for the treatment of cutaneous T-cell lymphoma (CTCL); however, its use provokes or disrupts other retinoid-X-receptor (RXR)-dependent nuclear receptor pathways and thereby incites side effects including hypothyroidism and raised triglycerides. Two novel bexarotene...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurutka, Peter W., di Martino, Orsola, Reshi, Sabeeha, Mallick, Sanchita, Sausedo, Michael A., Moen, Grant A., Lee, Isaac J., Ivan, Dominic J., Krall, Tyler D., Peoples, Samuel J., Perez, Anthony, Tromba, Lucas, Le, Anh, Khadka, Iraj, Petros, Ryan, Savage, Brianna M., Salama, Eleine, Salama, Jakline, Ziller, Joseph W., Noh, Youngbin, Lee, Ming-Yue, Liu, Wei, Welch, John S., Marshall, Pamela A., Wagner, Carl E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782500/
https://www.ncbi.nlm.nih.gov/pubmed/36555852
http://dx.doi.org/10.3390/ijms232416213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782500/
https://www.ncbi.nlm.nih.gov/pubmed/36555852
http://dx.doi.org/10.3390/ijms232416213

Ejemplares similares